---
title: Milestones & Achievements
permalink: /milestones-and-achievements/
variant: tiptap
description: ""
---
<div data-type="detailGroup" class="isomer-accordion isomer-accordion-white">
<details class="isomer-details">
<summary><strong>üèÜ 2025: Certification &amp; First Delivery</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>From Vision to Patient Impact</em></strong>
</p>
<p>Following its first Health Sciences Authority (HSA) inspection, ACTRIS
achieved Good Manufacturing Practice (GMP) Certification and received a
Manufacturer‚Äôs Licence for investigational and specially authorised cell
therapy products for use in local hospitals.</p>
<p>&nbsp;</p>
<p>In July 2025, ACTRIS successfully delivered its first product under the
innovative salvage therapy framework that brought renewed hope and extended
care to a patient in need.</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>üöÄ 2023 - 2024: National Launch &amp; Expansion</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>Official Launch &amp; Early Impact</em></strong>
</p>
<p>On 23 August 2023, the Minister for Health officially launched the ACTRIS
facility ‚Äî Singapore‚Äôs largest national manufacturing facility for CGT
‚Äî affirming its role as a cornerstone of the nation‚Äôs growing CGT ecosystem.</p>
<div class="isomer-image-wrapper">
<img style="width: 50%;" height="auto" width="100%" alt="" src="/images/Newsroom &amp; Events/Events/ACTRIS_Launch_P1.jpg">
</div>
<p></p>
<p>ACTRIS began onboarding early collaborative projects to support the manufacture
of investigational CGT products.</p>
<p>ACTRIS secured RIE2025 funding to advance research translation, enhance
process development capabilities with A*STAR Bioprocessing Technology Institute
(BTI), and expand manufacturing of investigational CGT products.</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>üõ†Ô∏è 2021 - 2022: Resilence &amp; Readiness - Facility Comes to Life</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>Constructing Capabilities: ACTRIS Advances amidst Global Challenges</em></strong>
</p>
<p>Despite the global disruption of COVID-19, ACTRIS pressed on ‚Äî designing
and constructing a state-of-the-art facility, installing specialised equipment,
and strengthening awareness of its role within Singapore‚Äôs CGT ecosystem.</p>
<p>ACTRIS secured baseline operational funding to recruit and train critical
expertise and commission the facility essential for national readiness.</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>üî¨ 2019 - 2020: Infrastructure &amp; Identity - ACTRIS Emerges</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>Turning Plans into National Capabilities</em></strong>
</p>
<p>As plans matured, the focus turned to capability building. NCTC IO secured
government funding for infrastructure ‚Äî paving the way for a national facility
to accelerate CGT development and access.</p>
<p>Building on this foundation, NCTC evolved into ACTRIS ‚Äî the Advanced Cell
Therapy and Research Institute, Singapore ‚Äî and on 20 April 2020, became
part of the Consortium for Clinical Research and Innovation, Singapore
(CRIS).</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>üèóÔ∏è 2017 - 2018: Strategic Foundations - Building the Framework</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>Establishing the NCTC Implementation Office: Strategy Meets Structure</em></strong>
</p>
<p>To translate this vision into action, the NCTC Implementation Office (IO)
was established to define strategy, governance, and resource requirements.
The IO laid a strong foundation to enable research translation and enhance
clinical access to CGTs.</p>
</div>
</details>
<details class="isomer-details">
<summary><strong>üå± 2015 - 2016: Vision Ignited - Laying the Groundword for CGT in Singapore</strong>
</summary>
<div data-type="detailsContent" class="isomer-details-content">
<p><strong><em>From Vision to Blueprint: The Birth of National Cell Therapy Centre</em></strong>
</p>
<p>It began with a vision ‚Äî to make cell and gene therapy (CGT) a reality
for patients in Singapore and beyond. Guided by the Ministry of Health‚Äôs
(MOH) National Cell Therapy Services Advisory Committee, the concept of
a National Cell Therapy Centre (NCTC) took shape through extensive horizon
scanning, global benchmarking, and strategic engagement with hospitals,
research institutes, and industry partners.</p>
</div>
</details>
</div>
<p></p>